Please assess the completion status of the following clinical trial:

Trial Title: Study of Stereotactic Body Radiation Therapy Using Tomotherapy for Metastatic Tumors to the Liver

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of solid primary tumor metastatic to liver~* Age greater than or equal to 18 years old~* Zubrod performance status less than or equal to 1~* Negative pregnancy test for women of child bearing potential~* Informed consent~* Less than or equal to 3 liver metastases~* Each lesion must be less than or equal to 6 cm in maximal diameter~* No prior radiation to lesions being treated~* Patient is not a surgical candidate or refuses surgery~* Absolute neutrophil count ≥ 1800~* Platelets ≥ 100000~* Hemoglobin ≥8.0~* Systemic therapy (chemotherapy) completed at least 2 weeks prior to SBRT~* At time of radiation treatment planning, at least 700 cc of normal liver must receive less than 15 Gy~Exclusion Criteria:~* Contraindications to radiation~* Pregnant or lactating females who chose to breast feed~* Patients must have recovered from toxicity of prior therapy~* Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications~* Patients currently receiving anticoagulation with coumadin or IV heparin~* Liver cirrhosis~* Clinical ascites~* Bilirubin \> 3, Albumin \< 2.5, liver enzymes 3 times above normal, Creatinine \> 1.8

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tomotherapy (Type: EXPERIMENTAL): Intervention: Stereotactic Body Radiation Therapy using Tomotherapy. Tomotherapy treatment: A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the PTV.

Based on this trial design, predict the completion outcome and termination type (if applicable).